Tearsheet

Hinge Health (HNGE)


Market Price (2/16/2026): $39.0 | Market Cap: $3.1 Bil
Sector: Health Care | Industry: Health Care Technology

Hinge Health (HNGE)


Market Price (2/16/2026): $39.0
Market Cap: $3.1 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%
Weak multi-year price returns
2Y Excs Rtn is -32%, 3Y Excs Rtn is -62%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -553 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51%
  Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 117%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26%
  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.
  Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.
4 Weak multi-year price returns
2Y Excs Rtn is -32%, 3Y Excs Rtn is -62%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -553 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 117%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22%
8 Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Hinge Health (HNGE) stock has lost about 20% since 10/31/2025 because of the following key factors:

1. Analyst Price Target Reductions and Cautious Outlook.

Despite reporting strong financial results for Q4 2025, several analysts revised down their price targets for Hinge Health (HNGE) during the period, signaling a more conservative valuation or outlook on future growth. For instance, Barclays cut its target from $60.00 to $52.00 on February 11, 2026, Piper Sandler lowered its target from $71.00 to $60.00 in January 2026, and Keybanc reduced its target from $72.00 to $70.00, also in January 2026. These adjustments, even with positive current performance, contributed to a bearish sentiment and downward pressure on the stock.

2. Broader Market Sentiment and Valuation Concerns for Growth Stocks.

Hinge Health's stock has faced ongoing pressure since its Initial Public Offering in May 2025, often trading near its 52-week low despite generally supportive analyst ratings. The company appears to have been impacted by broader investor rotations away from high-growth, technology-enabled healthcare companies, particularly those that may not yet consistently demonstrate GAAP profitability. Although Hinge Health achieved GAAP profitability in Q4 2025, it still reported a full-year loss for 2025, which likely contributed to investor caution regarding its long-term valuation and sustained profitability.

Show more

Stock Movement Drivers

Fundamental Drivers

The -21.7% change in HNGE stock from 10/31/2025 to 2/15/2026 was primarily driven by a -26.0% change in the company's P/S Multiple.
(LTM values as of)103120252152026Change
Stock Price ($)49.7638.94-21.7%
Change Contribution By: 
Total Revenues ($ Mil)3353555.7%
P/S Multiple10.27.5-26.0%
Shares Outstanding (Mil)69690.0%
Cumulative Contribution-21.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/15/2026
ReturnCorrelation
HNGE-21.7% 
Market (SPY)-0.0%11.2%
Sector (XLV)9.3%7.3%

Fundamental Drivers

The -13.4% change in HNGE stock from 7/31/2025 to 2/15/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
(LTM values as of)73120252152026Change
Stock Price ($)44.9538.94-13.4%
Change Contribution By: 
Total Revenues ($ Mil)3550.0%
P/S Multiple7.50.0%
Shares Outstanding (Mil)69690.0%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/15/2026
ReturnCorrelation
HNGE-13.4% 
Market (SPY)8.2%21.6%
Sector (XLV)21.4%3.1%

Fundamental Drivers

null
null

Market Drivers

1/31/2025 to 2/15/2026
ReturnCorrelation
HNGE  
Market (SPY)14.3%22.5%
Sector (XLV)8.8%1.9%

Fundamental Drivers

null
null

Market Drivers

1/31/2023 to 2/15/2026
ReturnCorrelation
HNGE  
Market (SPY)74.0%22.5%
Sector (XLV)23.7%1.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HNGE Return----24%-15%5%
Peers Return-46%-65%-39%-63%-28%-16%-97%
S&P 500 Return27%-19%24%23%16%-0%82%

Monthly Win Rates [3]
HNGE Win Rate----50%50% 
Peers Win Rate31%25%44%33%28%17% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
HNGE Max Drawdown-----7%-33% 
Peers Max Drawdown-53%-68%-59%-71%-58%-21% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)

How Low Can It Go

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,100 days1,480 days

Compare to TDOC, AMWL, DRIO

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Hinge Health (HNGE)

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Hinge Health:

  • Peloton for physical therapy and musculoskeletal health: Hinge Health brings guided exercise programs and coaching for back and joint pain directly into people's homes, similar to how Peloton provides fitness classes.
  • Teladoc for chronic back and joint pain: Hinge Health offers specialized virtual care, including physical therapy and health coaching, specifically for musculoskeletal conditions, much like Teladoc provides general virtual doctor visits.

AI Analysis | Feedback

  • Digital Musculoskeletal (MSK) Program: Provides virtual physical therapy, health coaching, and educational content for individuals experiencing chronic or acute joint and muscle pain.
  • Preventive MSK Program: Offers personalized exercise routines and educational resources designed to help individuals prevent the onset or worsening of musculoskeletal conditions.
  • Surgical Pathway Program: Delivers pre-operative and post-operative support, including personalized exercise plans and guidance, for members undergoing musculoskeletal surgery.
  • Women's Pelvic Health Program: A specialized virtual program offering exercises and coaching to address conditions related to pelvic floor dysfunction, such as incontinence or pelvic pain.

AI Analysis | Feedback

Hinge Health (symbol: HNGE) primarily sells its digital musculoskeletal (MSK) solutions to other companies (B2B).

While Hinge Health serves a broad base of over 1,500 customers and does not typically disclose specific "major customers" by name in its public filings (as no single customer accounts for a material portion of its revenue), their customer base consists primarily of two categories of large organizations:

  • Large Employers: Hinge Health partners with a significant portion of the Fortune 500, including 96% of these companies. These customers are diverse across various industries, offering Hinge Health's solutions as an employee benefit. While specific names of individual major customers are not disclosed by Hinge Health, examples of companies within the Fortune 500 that represent their target client base include:
    • Walmart (WMT)
    • Amazon (AMZN)
    • Apple (AAPL)
    • Microsoft (MSFT)
    • Alphabet (GOOGL)
  • Major Health Plans: Hinge Health works with some of the largest health plans in the United States, including 11 of the top 15. These health plans often offer Hinge Health's solutions to their members or through employer benefit programs. Examples of such major health plans that are public companies include:
    • UnitedHealth Group (UNH)
    • Elevance Health (ELV)
    • Cigna Group (CI)
    • CVS Health (CVS) (which includes Aetna)

AI Analysis | Feedback

  • Amazon.com, Inc. (AMZN) - for Amazon Web Services (AWS)

AI Analysis | Feedback

Daniel Perez, Chief Executive Officer

Daniel Perez co-founded Hinge Health in 2014, inspired by his personal experiences with musculoskeletal injuries. He holds a B.S. in Biology from Westminster University and attended a DPhil (PhD) program in biochemistry at Oxford University. Prior to Hinge Health, he co-founded Marblar in 2011 and the Oxbridge Biotech Roundtable, and Hinge Health is the third company he and Gabriel Mecklenburg have co-founded and run together. Under his leadership, Hinge Health has treated over 1.5 million people and raised over $800M in venture financing before going public.

James Budge, Chief Financial Officer

James Budge has served as the Chief Financial Officer of Hinge Health since March 2023. He previously held CFO positions at Automation Anywhere, Pluralsight, and Anaplan. Before these roles, he was the Chief Financial Officer and Chief Operating Officer at Genesys Cloud Services and Rovi Corporation. Mr. Budge holds a B.S. in Accounting from Brigham Young University.

Gabriel Mecklenburg, Executive Chairman

Gabriel Mecklenburg co-founded Hinge Health in 2014 with Daniel Perez. He also served as the company's Chief Operating Officer from October 2014 to February 2021. He was previously the Chief Operating Officer at Oxbridge Biotech Roundtable Ltd. and co-founded Marblar, a product development company focused on healthcare. Mr. Mecklenburg holds an M.Sc. in Materials Science from the University of Cambridge and an M.Phil. in Bioengineering from Imperial College London. He also serves on the board of directors of Pelago Health.

Jim Pursley, President

Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer for Livongo Health, where he was part of the founding executive team that took the company public in 2019, ultimately leading to an $18.5 billion acquisition by Teladoc Health. He also held various executive roles at Care Innovations and GE HealthCare Technologies. Mr. Pursley earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.

Dr. Jeffrey Krauss, Chief Medical Officer

Dr. Jeffrey Krauss joined Hinge Health as Chief Medical Officer in September 2018. He graduated from Harvard College, received his medical degree from the UC San Francisco School of Medicine, and completed his residency in physical medicine and rehabilitation (PM&R) at Stanford University. He is board-certified in PM&R and Lifestyle Medicine and is a clinical assistant professor at Stanford. Before his medical career, Dr. Krauss worked in product management for eight years at eBay and Oracle.

AI Analysis | Feedback

Hinge Health (NYSE: HNGE) faces several key risks to its business as a publicly traded company in the digital musculoskeletal (MSK) care market.

Key Risks to Hinge Health's Business

1. Intense Competitive Pressures and Market Commoditization: Hinge Health operates in a highly competitive digital MSK care market, facing rivals such as Omada Health, Sword Health, and Kaia Health, as well as traditional healthcare providers developing similar solutions. This intense competition can lead to increased pricing pressure, heightened customer expectations, and challenges in maintaining client retention and differentiation. The potential for commoditization of digital MSK programs, especially in cost-cutting environments, poses a significant threat to Hinge Health's premium pricing position, as its technological advantages in AI-powered motion tracking could be replicated by competitors.

2. Profitability Concerns and High Valuation: Despite demonstrating robust revenue growth, Hinge Health has reported GAAP losses, which have been influenced by substantial stock-based compensation. These ongoing losses raise concerns about long-term profitability and potential shareholder dilution. The company's elevated forward Price/Book multiple, significantly higher than industry averages, suggests that investors have high expectations for future growth and profitability. Any deceleration in revenue growth or difficulties in expanding beyond its core MSK offerings could lead to a sharp repricing of the stock, impacting investor confidence.

3. Regulatory and Data Privacy Risks: Operating within the heavily regulated healthcare sector, Hinge Health is exposed to significant regulatory and legal challenges, particularly concerning data privacy and the use of artificial intelligence in healthcare. Compliance with evolving regulations, such as those related to data protection (e.g., HIPAA), could incur substantial costs and operational complexities, potentially impacting the company's financial performance and operational efficiency. Increased regulatory scrutiny of AI in healthcare also presents an ongoing risk.

AI Analysis | Feedback

The increasing demand from employers and health plans for consolidated, integrated digital health platforms that address multiple chronic conditions (e.g., musculoskeletal, diabetes, hypertension, mental health) rather than individual point solutions. This trend pressures Hinge Health, historically a leading point solution for musculoskeletal care, to rapidly expand its scope or risk being at a disadvantage compared to competitors (such as Omada Health, DarioHealth, or even larger telehealth providers) that offer broader, bundled solutions. This also makes Hinge Health vulnerable to employers and payers opting to partner with fewer, more comprehensive vendors to reduce "vendor fatigue" and streamline benefits management.

AI Analysis | Feedback

Hinge Health primarily offers a digital clinic for musculoskeletal (MSK) care, providing personalized online physical therapy programs, AI-powered motion tracking, and access to physical therapists and health coaches. They also provide an FDA-cleared wearable device called Enso for pain relief. Hinge Health targets self-insured employers and health plans.

The addressable markets for Hinge Health's main products and services are significant:

  • The total musculoskeletal (MSK) care burden in the U.S. is estimated at $1.3 trillion annually, comprising $661 billion in direct spend and an additional $624 billion in indirect costs.

  • Within the broader digital health for musculoskeletal care market, the global market size was estimated at approximately $4.44 billion in 2024 and is projected to reach $11.64 billion by 2030, with a compound annual growth rate (CAGR) of 17.7% from 2025 to 2030.

  • Focusing on the U.S., the digital health for musculoskeletal care market generated an estimated revenue of $1.30 billion in 2024 and is expected to grow to $3.09 billion by 2030, at a CAGR of 15.5% from 2025 to 2030. The U.S. accounted for 29.4% of the global digital health for musculoskeletal care market in 2024.

  • Hinge Health's specific addressable market within the U.S. includes its current self-insured employer market, which represents an approximate $10 billion opportunity.

  • Adjacent market opportunities in the U.S. include fully-insured employers and Medicare Advantage plans, which constitute an $8 billion addressable market with 96 million additional lives, and government agencies and healthcare programs (Medicare/Medicaid), offering another $9 billion opportunity with 112 million lives.

  • Physical therapy, a core service for Hinge Health, represents a $60 billion-plus market in the United States, despite being only 1.2% of total healthcare spending.

AI Analysis | Feedback

Hinge Health (HNGE) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

  1. Growth in Client Base and Member Enrollment: Hinge Health's revenue model is directly tied to the number of eligible lives and the percentage of those who enroll and engage with their programs (yield). The company has consistently expanded its client base, including large employers, and focuses on increasing eligible lives through new client acquisitions and further penetration within existing accounts. This continued expansion of clients and successful enrollment initiatives are crucial for revenue growth.
  2. Expansion into New Markets: The company is actively diversifying its revenue streams beyond its core self-insured employer market. This includes strategic expansion into fully-insured health plans, Medicare Advantage, and global markets. For example, Hinge Health began international expansion in Canada in Q3 2024 and plans European launches for 2025, which will open up significant new revenue opportunities.
  3. New Product and Service Innovation, particularly AI-Powered Offerings: Hinge Health is continually investing in research and development to launch new products and enhance existing services. Key initiatives include its AI-powered platform for automated care delivery, such as the AI care assistant "Robin" and advanced motion analysis capabilities, which improve efficiency and outcomes. Additionally, the launch of HingeSelect, a network of in-person providers, is designed to offer a more comprehensive musculoskeletal (MSK) care model and tap into new patient segments. The company is also exploring new focus areas beyond MSK, such as women's health.
  4. Leveraging an Engagement-Based Pricing Model and Improved Operational Efficiency: Hinge Health's revenue model incorporates an engagement-based pricing structure, where clients pay for members who actively engage. The company's AI-driven platform significantly improves operational efficiency, leading to higher gross margins and the ability to scale its technology-driven care model more effectively. This scalability and focus on engagement ensure that revenue growth is supported by efficient service delivery and strong member utilization.

AI Analysis | Feedback

Share Issuance

  • Hinge Health issued 8.5 million shares in its Initial Public Offering (IPO) in May 2025.
  • The IPO was priced at $32 per share, raising $437 million for the company.
  • A total of 13.7 million shares were part of the IPO, including 5.2 million shares sold by existing shareholders.

Inbound Investments

  • In October 2021, Hinge Health secured $400 million in Series E financing, achieving a valuation of $6.2 billion.
  • Prior to that, in January 2021, the company completed a $300 million Series D funding round, which valued the company at $3 billion.
  • Over $1 billion had been invested in Hinge Health by October 2021, supporting the development of its clinical, data science, and R&D teams.

Outbound Investments

  • Hinge Health has made acquisitions, including wrnch and Enso Relief.

Trade Ideas

Select ideas related to HNGE.

Unique Key

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Price38.944.655.4011.728.56
Mkt Cap3.10.80.10.00.5
Rev LTM5342,52824925392
Op Inc LTM-553-179-105-40-142
FCF LTM141140-66-2757
FCF 3Y Avg-153-124-33-33
CFO LTM146293-66-2760
CFO 3Y Avg-305-114-32-32

Growth & Margins

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Rev Chg LTM50.7%-2.4%-2.0%7.3%2.7%
Rev Chg 3Y Avg-3.0%-3.4%-2.4%-2.4%
Rev Chg Q53.3%-2.2%-22.1%-32.5%-12.2%
QoQ Delta Rev Chg LTM11.1%-0.6%-5.9%-8.9%-3.2%
Op Mgn LTM-103.4%-7.1%-42.2%-160.8%-72.8%
Op Mgn 3Y Avg--7.6%-75.5%-213.0%-75.5%
QoQ Delta Op Mgn LTM11.1%0.2%4.1%-4.9%2.1%
CFO/Rev LTM27.3%11.6%-26.5%-108.3%-7.4%
CFO/Rev 3Y Avg-11.9%-44.6%-136.6%-44.6%
FCF/Rev LTM26.4%5.5%-26.5%-108.9%-10.5%
FCF/Rev 3Y Avg-6.0%-48.6%-137.9%-48.6%

Valuation

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Cap3.10.80.10.00.5
P/S5.70.30.41.50.9
P/EBIT-5.6-3.6-0.8-0.7-2.2
P/E-5.8-3.7-0.9-0.9-2.3
P/CFO21.02.8-1.3-1.40.7
Total Yield-17.4%-27.2%-108.0%-115.1%-67.6%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-9.2%-82.6%-1,275.5%-82.6%
D/E0.01.30.10.90.5
Net D/E-0.20.4-2.0-0.0-0.1

Returns

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
1M Rtn-10.1%-26.0%14.6%-5.8%-8.0%
3M Rtn-4.9%-32.8%33.3%-0.1%-2.5%
6M Rtn-34.1%-38.2%-24.5%30.8%-29.3%
12M Rtn3.7%-67.6%-55.6%-16.3%-35.9%
3Y Rtn3.7%-84.7%-93.0%-88.9%-86.8%
1M Excs Rtn-8.8%-28.3%15.5%0.3%-4.3%
3M Excs Rtn-7.8%-37.5%31.6%-0.0%-3.9%
6M Excs Rtn-37.6%-42.0%-31.4%28.8%-34.5%
12M Excs Rtn-9.3%-75.9%-69.2%-18.6%-43.9%
3Y Excs Rtn-62.3%-151.1%-159.0%-155.6%-153.3%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2024
Single Segment293
Total293


Net Income by Segment
$ Mil2024
Single Segment-108
Total-108


Short Interest

Short Interest: As Of Date1302026
Short Interest: Shares Quantity4.6 Mil
Short Interest: % Change Since 1152026-4.1%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest4.9 days
Basic Shares Quantity78.9 Mil
Short % of Basic Shares5.8%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/10/2026   
11/4/2025-15.1%-17.1%-6.4%
8/5/202525.6%16.1%16.2%
SUMMARY STATS   
# Positive111
# Negative111
Median Positive25.6%16.1%16.2%
Median Negative-15.1%-17.1%-6.4%
Max Positive25.6%16.1%16.2%
Max Negative-15.1%-17.1%-6.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202511/07/202510-Q
06/30/202508/11/202510-Q
03/31/202505/23/2025424B4

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Perez, Daniel AntonioCEO & Co-FounderDirectSell106202646.38166,665  Form
2Pursley, JamesPresidentDirectSell1223202548.4015,000725,95037,254,715Form
3Budge, JamesChief Financial OfficerDirectSell1223202548.4110,491507,83721,355,866Form
4Perez, Daniel AntonioCEO & Co-FounderDirectSell1216202548.53166,670  Form
5Robinson, Elliott See footnoteSell120920250.000  Form